Ligand Pharmaceuticals Reports 15% Revenue Growth to $47.6 Million in Q2 2025

Ligand Pharmaceuticals Incorporated reported a total revenue of $47.6 million for the second quarter of 2025, marking a 15% increase from $41.5 million in the same period last year. The growth was primarily driven by a significant rise in royalties, which surged by 57% to $36.4 million, attributed to increased sales from the Qarziba financial royalty asset and higher sales of Filspari. Additionally, revenue from intangible royalty assets rose by 33% to $30.1 million, while Captisol sales increased by 10% to $8.3 million. However, contract revenue and other income saw a notable decline of 73%, falling to $2.9 million due to the timing of partner milestone events.

In terms of profitability, Ligand reported a net income of $4.8 million for Q2 2025, a significant turnaround from a net loss of $51.9 million in Q2 2024. This improvement was supported by a decrease in total operating costs and expenses, which fell by 35% to $39.2 million, largely due to the absence of a financial royalty asset impairment that had impacted the previous year’s results. The company’s operating income for the quarter was $8.4 million, compared to an operating loss of $19.1 million in the prior year.

Strategically, Ligand has made significant moves, including the completion of a merger involving its subsidiary, Pelthos Therapeutics, which was finalized on July 2, 2025. This merger allowed Pelthos to raise $50.1 million in equity capital, with Ligand contributing $18 million. Following the merger, Pelthos launched Zelsuvmi, the first FDA-approved at-home treatment for molluscum contagiosum, on July 10, 2025. Ligand is entitled to a 13% royalty on worldwide sales of Zelsuvmi, excluding Japan, and has the potential to earn additional commercial sales milestones.

Operationally, Ligand's total assets increased slightly to $948.6 million as of June 30, 2025, compared to $941.8 million at the end of 2024. The company’s cash and cash equivalents stood at $67.7 million, down from $72.3 million at the end of the previous year. Ligand's employee headcount has also seen changes, reflecting its ongoing strategic initiatives and operational adjustments. The company continues to focus on expanding its portfolio through acquisitions and partnerships, as evidenced by its recent investments in Orchestra BioMed and the Castle Creek transaction, which are expected to enhance its revenue-generating capabilities in the biopharmaceutical sector.

Looking ahead, Ligand remains optimistic about its growth trajectory, driven by its diverse portfolio of royalty assets and ongoing partnerships with leading biopharmaceutical companies. The company anticipates continued revenue growth from its royalty streams and product sales, although it acknowledges the inherent risks and uncertainties associated with the biopharmaceutical industry, including regulatory approvals and market conditions.